Form 4 for EDSA Edesa Biotech, Inc.
Accepted 2026-03-02 00:00:00 ET · period of report 2026-02-26 · accession 0001171843-26-001267 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | 2026-03-02 | EDSA | Nijhawan Pardeep | CEO, Dir, 10% | A - Grant | $0.00 | +10.0K | 625.8K | +2% | $0 | |
| 2026-03-02 | 2026-02-26 | EDSA | Nijhawan Pardeep | CEO, Dir, 10% | P - Purchase | $1.58 | +20.6K | 615.8K | +3% | +$32.5K | |
| I | 2026-03-02 | 2026-02-27 | EDSA | Nijhawan Pardeep | CEO, Dir, 10% | P - Purchase | $2.22 | +30.0K | 371.7K | +9% | +$66.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-03-02 | A | A | 10,016 | $0.00 | 625,813 | D | — | — | (F2) Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. |
| 2 | Common | Common Shares | 2026-02-26 | P | A | 20,571 | $1.58 | 615,797 | D Held by Pardeep Nijhawan Medicine Professional Corporation | — | — | (F1) The price reported in this Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.54 to $1.58 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. (F4) Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| 3 | Common | Common Shares | 2026-02-27 | P | A | 30,000 | $2.22 | 371,702 | I | — | — | (F3) The price reported in this Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.22 to $2.2295 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |